Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ACP3 | P15309 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6203867 | 0.77 | CHRNA7 (0.41) | KMT2ATSHRALDH1A1GAA | |
| SCHEMBL6202338 | 0.77 | CYP1A2 (0.43) | KMT2AALDH1A1HPGD | |
| SCHEMBL6205148 | 0.75 | ADRB2 (0.44) | IDO1TDO2TSHRHPGD | |
| SCHEMBL6205817 | 0.75 | CA1 (0.52) | KMT2ACES2CES1ACP3CA12 | |
| SCHEMBL1357005 | 0.75 | ALDH1A1 (0.39) | KMT2ACES2CES1CYP2D6SRC | |
| SCHEMBL6206390 | 0.75 | AOC3 (0.44) | IDO1TDO2ALDH1A1GAAHPGD | |
| SCHEMBL6205041 | 0.75 | IDO1 (0.46) | KMT2AIDO1TDO2ALDH1A1GAA | |
| SCHEMBL9662373 | 0.75 | TSHR (0.41) | KMT2ACYP2D6TSHRHPGD | |
| SCHEMBL5168017 | 0.75 | AOC3 (0.49) | ACP3TSHRALDH1A1HPGD | |
| SCHEMBL4022188 | 0.74 | CES2 (0.46) | KMT2ACES2CES1CYP2D6SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 658 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936487-B | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-07-09 | — | — | CN | claimed |
| WO-2024111390-A1 | COMPOUND AND METHOD FOR PRODUCING SAME | 学校法人帝京大学 | 2024-05-30 | — | — | WO | claimed |
| EP-3870295-B1 | NOVEL TRICYCLIC COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2023-03-08 | — | — | EP | claimed |
| US-20210387996-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2021-12-16 | — | — | US | claimed |
| CN-112888480-A | Novel tricyclic compounds for the treatment and prevention of hepatitis b virus diseases | 豪夫迈·罗氏有限公司 | 2021-06-01 | — | — | CN | claimed |
| EP-3728214-A1 | SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2020-10-28 | — | — | EP | claimed |
| WO-2020191503-A1 | METHODS AND USES OF BROMANTANE AND DERIVATIVES THEREOF FOR TREATING LUNG DISEASE, FATTY LIVER DISEASE, AND KIDNEY DISORDERS | ALGERNON PHARMACEUTICALS INC. (CA) | 2020-10-01 | — | — | WO | claimed |
| WO-2020002090-A1 | SUBSTITUTED THIAZOLYLPYRROLONES, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-01-02 | — | — | WO | claimed |
| WO-2020002091-A1 | SUBSTITUTED THIAZOLYLPYRROLONES, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-01-02 | — | — | WO | claimed |
| EP-3558976-A1 | SUBSTITUTED AZOLYLPYRROLONES AND AZOLYLHYDANTOINES AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | Bayer CropScience Aktiengesellschaft (DE) | 2019-10-30 | — | — | EP | claimed |
| US-4734495-A | Process and intermediates for beta-lactam antibiotics | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1988-03-29 | — | — | US | claimed |
| US-4675400-A | FORM CONJUGATES WITH IMMUNOGLOBULINS; ANTITUMOR AGENTS | ELI LILLY AND COMPANY (US) | 1987-06-23 | — | — | US | claimed |
| US-4596676-A | Bifunctional ester derivatives of 4-desacetyl indole-dihydroindole alkaloids | LILLY INDUSTRIES LIMITED (GB) | 1986-06-24 | — | — | US | claimed |
| EP-0123441-A1 | Vincaleukoblastine derivatives | LILLY INDUSTRIES LIMITED (GB) | 1984-10-31 | — | — | EP | claimed |
| US-4331597-A | AMOXYCILLIN DERIVATIVES | MEIJI SEIKA KAISHA, LTD. (JP) | 1982-05-25 | — | — | US | claimed |
| US-4269990-A | CHEMICAL INTERMEDIATES FOR 1-UNSUBSTITUTED-2-(4-INDANYL- OR 5-NAPHTHYLAMINO)-2-IMIDAZOLINE, USEFUL AS DRUGS | BASF AKTIENGESELLSCHAFT (DE) | 1981-05-26 | — | — | US | claimed |
| US-4232151-A | ANTIBIOTICS | SHIONOGI & CO., LTD. (JP) | 1980-11-04 | — | — | US | claimed |
| US-4079181-A | INTERMEDIATES FOR 3-HYDROXY-3-CEPHEM COMPOUNDS | SHIONOGI & CO., LTD. (JA) | 1978-03-14 | — | — | US | claimed |
| US-4073902-A | ANTIMICROBIAL COMPOUNDS | CIBA-GEIGY CORPORATION (US) | 1978-02-14 | — | — | US | claimed |
| US-4009277-A | 1,2-Dialkyl-3,4,5-trisubstituted pyrazolium salts as fungicidal agents | AMERICAN CYANAMID COMPANY (US) | 1977-02-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387996-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | TOP2B, HAVCR2, SLC10A1 | KMT2A 1316/4885CES2 286/4885CES1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.